+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bioengineered Protein Drugs Market - Global Forecast to 2030- Product Image
Bioengineered Protein Drugs Market - Global Forecast to 2030- Product Image
Sale

Bioengineered Protein Drugs Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011369
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bioengineered Protein Drugs Market grew from USD 415.13 billion in 2024 to USD 448.38 billion in 2025. It is expected to continue growing at a CAGR of 7.86%, reaching USD 653.87 billion by 2030.

Bioengineered protein drugs have emerged as cornerstone therapies in modern medicine, addressing critical unmet needs across a broad spectrum of diseases. This class of therapeutics harnesses advances in recombinant DNA technology to deliver high specificity and enhanced safety profiles compared with conventional small molecules. As the global healthcare community grapples with rising prevalence of chronic and rare diseases, these biologics deliver targeted treatment modalities that can modulate complex biological pathways, offering new hope in areas such as oncology, immunology and metabolic disorders. The intellectual rigor of protein engineering, coupled with scalable manufacturing platforms, has enabled stakeholders to accelerate pipelines from bench to bedside. In parallel, regulatory agencies have crafted guidelines to streamline approval processes for biosimilars and next-generation biotherapeutics, creating a more predictable pathway for innovation. Moreover, digitalization in bioprocess monitoring and the integration of real-world evidence are enhancing outcome predictability and operational efficiency, setting the stage for the next wave of therapeutic breakthroughs. Within this dynamic environment, industry participants-from established pharmaceutical majors to emerging biotech innovators-must navigate an evolving landscape of technological breakthroughs, shifting policy frameworks, and intensified competition. This executive summary provides a strategic overview of the current state of bioengineered protein drugs, highlights transformative market shifts, and delivers actionable insights to guide decision-makers in capturing sustainable growth opportunities.

Transformative Shifts Reshaping the Protein Therapeutics Sector

Over the past decade, the protein therapeutics sector has undergone transformative shifts driven by breakthroughs in molecular engineering and platform technologies. Precision editing techniques such as CRISPR and novel fusion protein constructs have enabled the design of biologics with enhanced efficacy, improved half-life and reduced immunogenicity. Concurrently, the adoption of continuous bioprocessing and single-use systems has elevated production agility, reducing time to market and optimizing cost structures. Artificial intelligence and machine learning have become indispensable tools for in silico modeling, accelerating lead candidate selection and informing clinical trial design. On the regulatory front, harmonized guidelines for biosimilar pathways and adaptive licensing frameworks have lowered barriers to entry, fostering a more competitive ecosystem. In addition, the rise of digital biomarkers and decentralized trial models is reshaping stakeholder interactions, empowering patient-centric approaches. As a result, incumbent pharmaceutical companies and agile biotechs are increasingly forming strategic alliances to leverage complementary capabilities, driving a convergence of technological expertise and commercial scale. This redefinition of value creation underscores the need for nimble strategies that balance scientific innovation with operational excellence.

Cumulative Impact of United States Tariffs Implemented in 2025

In early 2025, newly implemented United States tariffs on key biomanufacturing inputs have exerted cumulative impacts across the bioengineered protein drugs value chain. Levies on critical reagents such as chromatography resins, single-use bioreactor components and high-grade cell culture media have introduced cost pressures that cascade from raw material procurement through to final product release. These measures have prompted manufacturers to reevaluate sourcing strategies, accelerate qualification of domestic suppliers and invest in dual-sourcing agreements to mitigate supply-chain risk. At the same time, downstream partners have faced margin compression, compelling a reprioritization of high-value pipelines and manufacturing footprints. In response, companies are expanding nearshore production capabilities and exploring toll-manufacturing partnerships to maintain competitive pricing. Moreover, ongoing dialogue with policymakers aims to clarify tariff schedules and advocate for exemptions on therapeutic-critical materials. While the short-term impact has manifested in increased unit costs and project timelines, this environment also catalyzes innovation in process intensification and modular manufacturing approaches. Ultimately, the industry’s ability to navigate these headwinds will depend on proactive supply-chain resilience measures and collaborative engagement with regulatory authorities.

Key Segmentation Insights Across Drug Type, Technology, Manufacturing, Molecules, Therapeutic Areas, Diseases, End-Users, and Distribution

Analysis by drug type reveals that blood factors compete alongside hormones, peptide cancer drugs, recombinant proteins and vaccines, each benefiting from distinct regulatory pathways and clinical development paradigms. Concurrent evaluation by underlying technology highlights the role of classical biochemistry protocols, hybridoma technology for monoclonal antibodies, recombinant DNA technology in gene-based constructs, and transgenic technology for humanized protein expression in non-traditional hosts. Turning to manufacturing processes, the field encompasses extraction and purification workflows-leveraging both chromatography and filtration-alongside fermentation bioprocessing, formulation development that integrates fill-finish operations and stability testing, and lyophilization techniques designed to extend shelf life. From a molecular perspective, large molecules command significant attention due to their complexity and therapeutic versatility, while peptides and small molecules continue to diversify the treatment landscape with ease of synthesis and tissue penetration advantages. A breakdown by therapeutic area underscores strong demand in cardiovascular diseases, infectious diseases, metabolic disorders, neurology and oncology, with immunotherapy and targeted therapy driving oncology pipelines. Examination by target disease shows strategic prioritization of cancer, diabetes-including both type 1 and type 2-obesity and rare diseases, each requiring bespoke clinical strategies. End-user segmentation confirms that hospitals, clinics, ambulatory surgical centers and research and academic institutes serve as primary administration sites. Lastly, distribution channel analysis points to hospital pharmacies, online pharmacies and retail pharmacies as critical conduits for patient access.

Key Regional Insights Across Americas, EMEA, and Asia-Pacific Markets

In the Americas, the United States remains the largest market, driven by a robust biopharmaceutical infrastructure, favorable reimbursement policies and leading clinical trial capacity, while Canada contributes through niche biotech clusters and collaborative research networks. Across Europe, the Middle East and Africa, established markets in Germany, the United Kingdom and France benefit from strong regulatory harmonization under the European Medicines Agency, complemented by emerging manufacturing hubs in the Gulf Cooperation Council states and South Africa. Regulatory frameworks in these regions continue to evolve, with accelerated assessment pathways and mutual recognition agreements enhancing cross-border product mobility. The Asia-Pacific region is experiencing rapid expansion, led by China’s strategic investments in biomanufacturing capacity, Japan’s advanced R&D ecosystems, and India’s growing contract development and manufacturing organizations. Additionally, regulatory agencies in these markets are adopting risk-based and biosimilar guidelines, reducing time to market and fostering local innovation. As a result, multinational companies are forging partnerships with regional players to navigate diverse regulatory environments and optimize market access strategies. These regional dynamics underscore the importance of tailored approaches to local pricing, reimbursement and partnership models.

Key Company Insights Driving Innovation and Market Leadership

Industry leaders such as Abbott Laboratories and Ambrx, Inc. have established foundational biomanufacturing platforms focused on novel protein scaffolds, while Amgen Inc. and AstraZeneca PLC leverage robust global pipelines spanning oncology and immunology. Baxter Healthcare and Bayer Pharmaceuticals optimize supply-chain resilience through strategic raw material reserves, and Bristol-Myers Squibb, CSL Ltd. and F. Hoffmann-La Roche AG invest heavily in targeted oncology programs and next-generation antibody formats. GlaxoSmithKline PLC and Grifols S.A. expand capacity for plasma-derived therapeutics, whereas Merck & Co., Inc. and Novartis AG pursue diversified modalities that integrate mRNA, viral vectors and recombinant proteins. Novo Nordisk A/S continues to dominate in metabolic disorders with peptide analogs and long-acting formulations, while Pfizer Inc. and Sanofi combine vaccine expertise with recombinant platforms to address global infectious disease threats. Polaris Group and Regeneron Pharmaceuticals Inc. are at the forefront of next-generation antibody engineering and bispecific constructs, and Takeda Pharmaceutical Co., Ltd. along with Aravive, Inc. accelerate research in rare diseases through precision protein design. These entities collectively set the competitive benchmark, driving both incremental and disruptive innovation across the bioengineered protein drug market.

Actionable Recommendations for Industry Leaders Seeking Competitive Advantage

To capitalize on emerging opportunities and navigate evolving market conditions, industry leaders should adopt a multifaceted strategy centered on innovation, agility and collaboration. First, investing in advanced data analytics and artificial intelligence platforms can accelerate candidate selection and streamline clinical trial design, reducing attrition rates and time to market. Simultaneously, strengthening supply-chain diversification by qualifying multiple suppliers, expanding regional manufacturing capacities and integrating modular continuous bioprocessing solutions will enhance resilience against tariff-induced cost pressures and global disruptions. Leaders should also engage in early and proactive dialogue with regulatory authorities to leverage accelerated approval pathways and align on quality standards, ensuring smoother market entry. Forming strategic partnerships and co-development alliances with biotech innovators can provide access to specialized expertise and novel technologies, augmenting internal capabilities. Furthermore, committing to sustainable manufacturing practices-including single-use systems and green chemistry initiatives-can reduce environmental impact and align with evolving stakeholder expectations. Finally, cultivating multidisciplinary talent pools that blend scientific, engineering and digital skill sets will be critical in maintaining competitive advantage and driving long-term growth.

Conclusion: Positioning for Sustainable Growth in an Evolving Therapeutic Landscape

In summary, the bioengineered protein drug market stands at a pivotal juncture, characterized by rapid technological advancements, evolving regulatory landscapes and intensified global competition. While emerging tariff structures present short-term challenges, they also catalyze investment in supply-chain resilience and process innovation. The detailed segmentation analysis highlights diverse opportunities across drug types, technologies, manufacturing processes, therapeutic areas and end-user channels, underscoring the importance of targeted strategies. Regional insights reveal that while established markets continue to dominate, high-growth potential in emerging regions demands localized approaches. Finally, the competitive intelligence on leading companies provides a clear view of best-in-class practices and partnership opportunities. By embracing data-driven decision-making, collaborative models and sustainable manufacturing, stakeholders can position themselves to capture value and deliver transformative therapies to patients worldwide.

Market Segmentation & Coverage

This research report categorizes the Bioengineered Protein Drugs Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Blood Factors
  • Hormones
  • Peptide Cancer Drugs
  • Recombinant Proteins
  • Vaccines
  • Biochemistry
  • Hybridoma Technology
  • Recombinant DNA Technology
  • Transgenic Technology
  • Extraction and Purification
    • Chromatography
    • Filtration
  • Fermentation
  • Formulation Development
    • Fill-finish
    • Stability Testing
  • Lyophilization
  • Large Molecules
  • Peptides
  • Small Molecules
  • Cardiovascular Diseases
  • Infectious Diseases
  • Metabolic Disorders
  • Neurology
  • Oncology
    • Immunotherapy
    • Targeted Therapy
  • Cancer
  • Diabetes
    • Type 1 Diabetes
    • Type 2 Diabetes
  • Obesity
  • Rare Diseases
  • Ambulatory Surgical Centers
  • Clinics
  • Hospitals
  • Research and Academic Institutes
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

This research report categorizes the Bioengineered Protein Drugs Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Bioengineered Protein Drugs Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Ambrx, Inc.
  • AMGEN INC.
  • Aravive, Inc.
  • Astrazeneca PLC
  • Baxter Healthcare
  • Bayer Pharmaceuticals
  • BRISTOL-MYERS SQUIBB
  • CSL LTD.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • GRIFOLS S.A.
  • Hoffman-la-Roche
  • MERCK & CO., INC.
  • NOVARTIS AG
  • NOVO NORDISK A/S
  • PFIZER INC.
  • Polaris Group
  • REGENERON PHARMACEUTICALS INC.
  • SANOFI
  • TAKEDA PHARMACEUTICAL CO., LTD.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bioengineered Protein Drugs Market, by Drug Type
8.1. Introduction
8.2. Blood Factors
8.3. Hormones
8.4. Peptide Cancer Drugs
8.5. Recombinant Proteins
8.6. Vaccines
9. Bioengineered Protein Drugs Market, by Technology
9.1. Introduction
9.2. Biochemistry
9.3. Hybridoma Technology
9.4. Recombinant DNA Technology
9.5. Transgenic Technology
10. Bioengineered Protein Drugs Market, by Manufacturing Process
10.1. Introduction
10.2. Extraction and Purification
10.2.1. Chromatography
10.2.2. Filtration
10.3. Fermentation
10.4. Formulation Development
10.4.1. Fill-finish
10.4.2. Stability Testing
10.5. Lyophilization
11. Bioengineered Protein Drugs Market, by Molecule Type
11.1. Introduction
11.2. Large Molecules
11.3. Peptides
11.4. Small Molecules
12. Bioengineered Protein Drugs Market, by Therapeutic Area
12.1. Introduction
12.2. Cardiovascular Diseases
12.3. Infectious Diseases
12.4. Metabolic Disorders
12.5. Neurology
12.6. Oncology
12.6.1. Immunotherapy
12.6.2. Targeted Therapy
13. Bioengineered Protein Drugs Market, by Target Disease
13.1. Introduction
13.2. Cancer
13.3. Diabetes
13.3.1. Type 1 Diabetes
13.3.2. Type 2 Diabetes
13.4. Obesity
13.5. Rare Diseases
14. Bioengineered Protein Drugs Market, by End-User
14.1. Introduction
14.2. Ambulatory Surgical Centers
14.3. Clinics
14.4. Hospitals
14.5. Research and Academic Institutes
15. Bioengineered Protein Drugs Market, by Distribution Channel
15.1. Introduction
15.2. Hospital Pharmacies
15.3. Online Pharmacies
15.4. Retail Pharmacies
16. Americas Bioengineered Protein Drugs Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Bioengineered Protein Drugs Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Bioengineered Protein Drugs Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Abbott Laboratories
19.3.2. Ambrx, Inc.
19.3.3. AMGEN INC.
19.3.4. Aravive, Inc.
19.3.5. Astrazeneca PLC
19.3.6. Baxter Healthcare
19.3.7. Bayer Pharmaceuticals
19.3.8. BRISTOL-MYERS SQUIBB
19.3.9. CSL LTD.
19.3.10. F. HOFFMANN-LA ROCHE AG
19.3.11. GLAXOSMITHKLINE PLC
19.3.12. GRIFOLS S.A.
19.3.13. Hoffman-la-Roche
19.3.14. MERCK & CO., INC.
19.3.15. NOVARTIS AG
19.3.16. NOVO NORDISK A/S
19.3.17. PFIZER INC.
19.3.18. Polaris Group
19.3.19. REGENERON PHARMACEUTICALS INC.
19.3.20. SANOFI
19.3.21. TAKEDA PHARMACEUTICAL CO., LTD.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. BIOENGINEERED PROTEIN DRUGS MARKET MULTI-CURRENCY
FIGURE 2. BIOENGINEERED PROTEIN DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. BIOENGINEERED PROTEIN DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOENGINEERED PROTEIN DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEPTIDE CANCER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BIOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FILTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FERMENTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FILL-FINISH, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STABILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY LYOPHILIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY LARGE MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 97. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 98. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 99. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 100. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 101. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 102. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 103. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 104. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 105. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 108. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 109. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 110. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 111. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 112. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 113. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 114. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 115. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 116. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 117. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 158. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 159. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 160. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 161. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 162. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 163. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 164. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 165. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 166. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 167. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 170. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 172. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 173. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 174. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 175. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 176. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 177. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 178. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 179. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 188. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 189. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 190. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 191. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 192. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 194. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 195. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 196. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 197. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 198. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 199. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 200. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 201. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 202. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 203. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 208. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 209. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 210. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 211. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 212. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 220. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 221. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 222. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 223. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 224. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 225. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 226. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 227. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 228. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 232. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 233. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 234. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 235. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 236. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 237. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 238. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 239. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 240. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 246. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 247. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 248. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 249. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 250. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 251. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 252. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 254. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 256. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 257. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 258. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 259. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 260. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 261. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 262. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 263. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 264. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 266. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 267. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 268. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 269. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 270. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 271. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 272. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 273. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 274. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 275. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 276. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 278. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 279. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 280. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 281. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 282. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 283. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 284. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 285. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 286. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 287. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 288. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TARGET DISEASE, 2018-2030 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 302. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 303. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 304. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 305. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY EXTRACTION AND PURIFICATION, 2018-2030 (USD MILLION)
TABLE 306. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 307. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 308. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 309. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 310. DENMARK BIO

Companies Mentioned

  • Abbott Laboratories
  • Ambrx, Inc.
  • AMGEN INC.
  • Aravive, Inc.
  • Astrazeneca PLC
  • Baxter Healthcare
  • Bayer Pharmaceuticals
  • BRISTOL-MYERS SQUIBB
  • CSL LTD.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • GRIFOLS S.A.
  • Hoffman-la-Roche
  • MERCK & CO., INC.
  • NOVARTIS AG
  • NOVO NORDISK A/S
  • PFIZER INC.
  • Polaris Group
  • REGENERON PHARMACEUTICALS INC.
  • SANOFI
  • TAKEDA PHARMACEUTICAL CO., LTD.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Bioengineered Protein Drugs - Global Strategic Business Report - Product Image

Bioengineered Protein Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Bioengineered Protein Drugs Market Report 2025 - Product Image

Bioengineered Protein Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Bioengineered Protein Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology - Product Image

Bioengineered Protein Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology

  • Report
  • 89 Pages
  • Global
From
Protein Therapeutics Market by Protein Function, Product Type - Global Forecast 2025-2030 - Product Image

Protein Therapeutics Market by Protein Function, Product Type - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Protein Therapeutics - Global Strategic Business Report - Product Image

Protein Therapeutics - Global Strategic Business Report

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.